Biotech IPOs' bleak streak Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 16 May, 2025

Join us as we break down the latest oncology data, spotlight standout pipelines, and explore what’s coming next — reserve your spot today.

spotlight In Focus The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease In Focus Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

news Novo Nordisk CEO to step down, timeline for successor unknown •  Peer Review Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock It's been three months without a biotech IPO 'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure RFK Jr. adopts new chikungunya vaccine guidance; other recommendations remain under review Regeneron scores $400M+ jury win in Amgen cholesterol drug spat

May 29 10:30am ET Optimizing the clinical research workforce - An industry analysis by Parexel sponsored by Parexel Jun 03 11:00am ET Building robust health system partnerships for life sciences sponsored by Advisory Board Jun 18 12:00pm ET Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery sponsored by Natera

Who are the LGBTQ+ leaders in the industry? Hear insights from the honorees giving voice and visibility to the LGBTQ+ presence in biopharma — join virtually and celebrate with us. Sign up now.

endpoints pharma New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B Eisai says Leqembi is headed for 'demand expansion phase' in US FDA warns Mayne Pharma over 'misleading' presentation slides on birth control pill

in case you missed it 1. Bristol Myers CEO says America’s biopharma pole position is not guaranteed 2. Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs 3. Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team 4. Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate